Injection for Allergy: Matching the Right Injection to the Right Diagnosis
There is no single 'injection for allergy' — there are four distinct categories: SCIT (subcutaneous immunotherapy — the only injection that modifies allergen-specific immunity), biologics (Xolair, Dupixent, Tezspire — block inflammatory pathways), depot corticosteroids (Kenalog-40, Depo-Medrol — symptomatic, discouraged for routine rhinitis), and epinephrine (emergency rescue only). Matching the right injection to the diagnosis is the foundational clinical step.
6 peer-reviewed sources
Injections for allergy span four drug classes: SCIT (allergen immunotherapy, disease-modifying), biologics (Xolair, Dupixent — anti-inflammatory), depot steroids (symptomatic only), and epinephrine (emergency rescue). Only SCIT modifies allergen-specific immune tolerance.
The essentials
The question 'what injection is used for allergy?' requires a category answer, not a single product name. Different allergic diseases and different clinical goals point to different injection categories:
Category 1: SCIT (Subcutaneous Immunotherapy) — for IgE-mediated allergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera venom hypersensitivity. The only injection that modifies the underlying allergen-specific immune disease per the AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1-S55, DOI 10.1016/j.jaci.2010.09.034). A 3-to-5-year course of escalating allergen extract injections inducing Treg expansion, Th2 downregulation, and IgG4 blocking-antibody production.
Category 2: Biologics — for severe allergic asthma, atopic dermatitis, chronic urticaria, and food allergy risk reduction. Xolair (omalizumab, anti-IgE, FDA 2003; food allergy indication February 16, 2024 via OUtMATCH trial, N Engl J Med 2024: 67% protection vs 7% placebo). Dupixent (dupilumab, anti-IL-4Rα, FDA March 2017 for atopic dermatitis, October 2018 for asthma). Tezspire (tezepelumab, anti-TSLP, FDA December 17, 2021 for severe asthma ≥12). Biologics are disease-control injections, not disease-modifying in the allergen-specific tolerance sense.
Category 3: Depot Corticosteroids — for acute/severe seasonal allergy symptoms in patients not responding to conventional pharmacotherapy. Kenalog-40 (triamcinolone acetonide, FDA 1965; label specifies 'intractable' cases only). Depo-Medrol (methylprednisolone acetate; per FDA label, 80-120 mg may relieve coryzal symptoms for several days to three weeks). The AAAAI/ACAAI Joint Task Force rhinitis practice parameter discourages routine use and contraindicates repeated injections due to HPA-axis suppression.
Category 4: Epinephrine — for anaphylaxis. EpiPen (FDA 1987), Auvi-Q (Kaléo, FDA 2012), neffy (epinephrine nasal spray, FDA August 9, 2024). Emergency-only rescue medications, not allergy treatment.
Before any injection-based allergy treatment, Curex's at-home IgE blood test with allergist review identifies which allergens are clinically relevant and whether allergen immunotherapy is appropriate.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Across injection categories, SCIT provides the only allergen-specific disease-modifying outcome. Cochrane meta-analysis (Calderón 2007) found SCIT symptom SMD -0.73 with disease-modifying remission persisting after the course ends. Xolair provides reactive protection during treatment but no lasting benefit after stopping. Depot steroids and epinephrine have no disease-modifying effect.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Which injection is used for allergic rhinitis?
For IgE-mediated allergic rhinitis, subcutaneous immunotherapy (SCIT) is the only injection that modifies the underlying disease per Cox 2011 Practice Parameter (DOI 10.1016/j.jaci.2010.09.034). Cochrane meta-analysis (Calderón 2007, 51 RCTs / 2,871 patients) found symptom SMD -0.73. Depot corticosteroids (Kenalog-40, Depo-Medrol) suppress rhinitis symptoms for several days to weeks but are not disease-modifying and are discouraged for routine use by the AAAAI/ACAAI. Biologics like Dupixent target asthma or atopic dermatitis phenotypes with rhinitis components, but are not first-line for allergic rhinitis without these comorbidities.
Which injection is used for bee sting allergy?
Venom immunotherapy (VIT) — a subcategory of SCIT using FDA-standardized venom extracts — is the injection used for Hymenoptera (bee, yellow jacket, wasp) sting allergy. Hunt KJ et al. (N Engl J Med 1978) established the foundational evidence. Cochrane review (Boyle RJ et al., 2012, PMID 23076950) confirmed efficacy: sting anaphylaxis occurred in 2.7% of VIT-treated patients versus 39.8% of untreated controls. Five FDA-standardized venom extracts are available: honey bee, yellow jacket, yellow hornet, white-faced hornet, and wasp. Ultra-rush VIT protocols can reach the 100 µg maintenance dose in 4 hours for high-risk patients.
What injection can be given for severe seasonal allergy symptoms?
For severe acute seasonal allergy symptoms not responding to conventional pharmacotherapy, a depot corticosteroid injection (Kenalog-40 or Depo-Medrol) can provide temporary relief for several days to weeks. However, the AAAAI/ACAAI Joint Task Force rhinitis practice parameter discourages this approach for routine allergic rhinitis and contraindicates repeated injections due to HPA-axis suppression. The FDA label for Kenalog specifies 'allergic states intractable to adequate trials of conventional treatment.' For long-term benefit, SCIT (allergy shot immunotherapy) is the appropriate treatment — it addresses the underlying disease rather than suppressing inflammation symptomatically.
What injection is used for food allergy?
SCIT (subcutaneous immunotherapy) is NOT standard of care for food allergies. For food allergy risk reduction, Xolair (omalizumab) received an FDA indication on February 16, 2024, based on the OUtMATCH trial (Wood RA et al., N Engl J Med 2024): 67% of patients on Xolair could tolerate at least 600 mg of peanut protein versus 7% on placebo. Oral immunotherapy (OIT) for peanut — Palforzia (peanut OIT) was FDA-approved in 2020 but is being commercially discontinued on July 31, 2026. Off-label OIT through specialized food-allergy clinics remains an option. For standard inhalant allergies (pollen, dust mites, cat), SCIT is the appropriate injection.
How do I know which allergy injection is right for me?
The right injection depends on the diagnosis: IgE-confirmed inhalant allergy (pollen, dust mite, cat, dog, mold) → SCIT (allergen immunotherapy). Severe allergic asthma, atopic dermatitis, or chronic urticaria → evaluate biologics (Xolair, Dupixent, Tezspire) with your allergist or pulmonologist. Acute refractory seasonal rhinitis → depot corticosteroid as a last resort, discouraged for routine use. Anaphylaxis history → epinephrine auto-injector (EpiPen, Auvi-Q, neffy) to carry at all times. IgE blood testing or skin testing confirms the diagnosis and identifies which allergens are driving symptoms — the necessary first step before any injection treatment decision.
Is there an injection that cures allergies permanently?
No injection permanently cures allergies in the absolute sense, but SCIT (allergen immunotherapy) produces the most durable disease modification available. Durham SR et al. (N Engl J Med 1999;341:468-475) demonstrated that a 3-4 year SCIT course produced clinical remission persisting for years after stopping — without further treatment. The mechanism involves long-lived plasma cells that continue producing allergen-specific IgG4 blocking antibodies in bone marrow niches after treatment ends. Some patients require retreatment 5-10 years later. No pharmacotherapy or biologic produces a comparable post-treatment disease-modifying benefit.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shot Medication: SCIT vs Biologics vs Steroids | Curex
Allergy shot medication (SCIT) is allergen extract — FDA CBER, not CDER. No branded SCIT product. Greer, ALK, HollisterStier supply extracts. Custom-mixed per patient. Durham 1999 remission.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreAllergy Shot For Humans: SCIT & SLIT Guide
Yes, there is an allergy shot for humans — subcutaneous immunotherapy (SCIT). Cochrane SMD −0.73, 3–5 yr course, at home via Curex $129/mo. Not Cytopoint.
Read moreDesensitization Therapy Allergy: SCIT Guide | Curex
Desensitization therapy for allergy is the older term for SCIT — confirmed by Noon 1911 Lancet. Different from drug desensitization. Cochrane 2007: symptom SMD -0.73.
Read morePollen Allergy Vaccine: SCIT, SLIT Tablets & WHO 1998 | Curex
Pollen allergy vaccine is endorsed by WHO 1998 (PMID 9802362). In the US, it means SCIT or FDA-approved SLIT tablets (Grastek, Oralair, Ragwitek). Not a one-time shot — 3-5 year course.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.